Deal Ticker: Kellerhals Carrard is proud to have advised Comphya SA on its CHF 7.5 million Series A financing round.

Transforming care for erectile dysfunction with breakthrough neurostimulation technology. 

Millions of men suffer from erectile dysfunction (ED) that is unresponsive to medication, facing limited and often invasive treatment options. @Comphya is on a mission to change that. 

Comphya SA, a medtech spin-off from EPFL Lausanne, has successfully closed the second tranche of an oversubscribed CHF 7.5 million Series A financing round. This second tranche fuels Comphya’s clinical momentum and growth as it pioneers the world’s first implantable neurostimulation therapy for ED following prostate cancer treatment.

Following highly encouraging first-in-human data from its Australian clinical trial, Comphya has now launched a U.S. pilot study at Johns Hopkins after securing FDA IDE approval earlier this year. The company is also preparing for a pivotal U.S. clinical trial planned for 2026 and expanding its ongoing Australian study to include additional patients. The funds raised will enable Comphya to accelerate these clinical programs, advance regulatory pathways, and continue developing ist groundbreaking CaverSTIM™ neurostimulator system – aiming to redefine the standard of care and dramatically improve quality of life for patients worldwide.

We are grateful for Comphya’s continued trust put in us and have advised Comphya on all legal aspects of this financing round. The Kellerhals Carrard team comprised of Karim Maizar (Partner, Corporate/VC) and Joséphine Marmy (of Counsel, Corporate/VC).

Congratulations to Pim van Wesel and Rodrigo Fraga as well as the entire Comphya team on achieving this significant milestone! 

We look forward to continuing to support your journey as you bring transformative medical innovation to the world.